UBS analyst Eliana Merle raised the firm’s price target on Madrigal Pharmaceuticals to $410 from $337 and keeps a Buy rating on the shares. The FDA’s approval for Madrigal’s Rezdiffra is a major clearing event, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDGL:
- Madrigal Pharmaceuticals’ Rezdiffra™ Wins Accelerated FDA Approval
- Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
- Madrigal Pharmaceuticals price target raised to $405 from $275 at H.C. Wainwright
- Madrigal Pharmaceuticals price target raised to $338 from $336 at Canaccord
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)